Last reviewed · How we verify
NCT04345510
Testing for COVID-19 Infection in Asymptomatic Persons
trial in COVID-19 Infection in 500 participants. Completed in 30 September 2021.
30 September 2021
Quick facts
| Lead sponsor | German Cancer Research Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 20 April 2020 |
| Primary completion | 30 September 2021 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across Germany |
Conditions studied
- COVID-19 Infection — all drugs for COVID-19 Infection →
Sponsor
German Cancer Research Center — full company profile →
Who can join
18 and older, any sex, with COVID-19 Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Intensive action has been taken around the globe to fight the corona virus SARS-COV-2 (COVID-19) pandemia. Clinical symptoms of the infection appear to be variable, from basically asymptomatic infections and mild, flu-like symptoms up to severe respiratory insufficiency, requiring mechanical ventilation at the intensive care unit, and death. Broad testing for COVID-19 infection has been proven difficult in clinical practice and hampered by limited resources. Urgently needed epidemiological data on the rate of silent, asymptomatic infections in the population and the percentage of individuals that have already developed immunity are still missing. Within this study we therefore plan to (i) determine the proportion of asymptomatic COVID-19 virus carriers in (a) German Cancer Research Center (DKFZ) employees, who work and are present at the center during the time of extended minimum operation and (b) in all DKFZ employees before onboarding when extended minimum operation has been terminated. We plan to (ii) develop a high-throughput assay for COVID-19 testing as well as (iii) a serum-based COVID-19 antibody assay. Finally, we will (iv) analyze for a possible correlation between oral microbiome and COVID-19 infection status.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis.
Viana SD, Nunes S, Reis F. · · 2020 · cited 122× · PMID 32683039 · DOI 10.1016/j.arr.2020.101123 -
The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort.
Newsome RC, Gauthier J, Hernandez MC, Abraham GE, et al · · 2021 · cited 58× · PMID 34100340 · DOI 10.1080/19490976.2021.1926840 -
Gut Microbiota Dysbiosis-Immune Hyperresponse-Inflammation Triad in Coronavirus Disease 2019 (COVID-19): Impact of Pharmacological and Nutraceutical Approaches.
Ferreira C, Viana SD, Reis F. · · 2020 · cited 44× · PMID 33019592 · DOI 10.3390/microorganisms8101514
Verify or expand the search:
- PubMed search for NCT04345510
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Infection
Currently open trials in the same condition.
- NCT07013474 — A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised · Phase 3 · recruiting
- NCT06965751 — A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 · Phase 1 · active not recruiting
- NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
- NCT05672355 — A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia · Phase 2 · recruiting
- NCT05774093 — Evaluation of COVID-19 Immune Barrier and Reinfection Risk · recruiting
Other German Cancer Research Center trials
Trials by the same sponsor.
- NCT06614673 — Cancer Literacy as an Essential Factor for Lifestyle Behavior Changes: An Observational and Interventional Study · NA · completed
- NCT06026384 — Evaluation of Text or Animation-based Narrative and Non-narrative Interventions to Enhance Cancer Literacy: a Pilot Stud · NA · completed
- NCT05999396 — FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer · Phase 1 · recruiting
- NCT05494866 — A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal · Phase 1 · terminated
- NCT06621810 — Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04345510 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by German Cancer Research Center
- Last refreshed: 29 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04345510.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing